Enterprise Value
374.5M
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
70.98%
Institutional Own.
3.59%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tinlarebant (LBS-008) Details Dry eye disease , Macular degeneration, Age-related macular degeneration | Phase 3 Initiation | |
Tinlarebant (LBS-008) Details Stargardt disease | Phase 2 Data readout |